ロード中...
A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma
BACKGROUND: Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer. The prognostic signature could be reliable to stratify LUAD patients according to risk, which helps the management of the systematic treatments. In this study, a systematic and reliable immune signature was performed...
保存先:
| 出版年: | J Transl Med |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7060601/ https://ncbi.nlm.nih.gov/pubmed/32143735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-020-02286-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|